❌

Reading view

Anonymization of Portuguese Clinical Notes Using Large Language Models and Quantum-Enhanced Hybrid Architectures: Comparative Evaluation Study

Background: The widespread adoption of electronic health records (EHRs) has generated large-scale repositories of highly sensitive clinical information, emphasizing the need for robust anonymization strategies to enable secondary use for research while safeguarding patient privacy. Conventional rule-based and machine learning approaches for deidentifying medical text face limitations with the linguistic complexity, variability, and context dependence inherent to clinical documentation. Recent advances in large language models (LLMs), combined with emerging quantum computing paradigms, present novel opportunities to enhance the accuracy, scalability, and resilience of health care data anonymization. Objective: This study aims to evaluate the efficacy of LLM-based and quantum-enhanced hybrid architectures for medical text anonymization, assessing the effectiveness and computational efficiency across multiple entity types in Portuguese clinical notes. Methods: We constructed a gold-standard corpus of 1000 Portuguese outpatient clinical notes, manually annotated by 5 trained researchers for 5 protected-entity categories: patient names, dates, identifiers, organizations, and geographic locations. Four anonymization strategies were evaluated: 2 stand-alone LLMs (Llama-3.1-8B-instruct and Llama-3.3-70B-instruct) and 2 quantum-enhanced hybrid models (Dynex-QML with 8B and 70B base models) incorporating quantum optimization via Quadratic Unconstrained Binary Optimization (QUBO) formulations. The quantum-enhanced approach transforms the final attention layer of the LLM into a global constraint satisfaction problem solved via neuromorphic quantum annealing. Model performance was measured on a held-out test set of 500 notes using precision, recall, and -score metrics. Computational efficiency was quantified through end-to-end processing time. Results: The quantum-enhanced Dynex-QML-70B model achieved the highest overall performance with a macro-score of 0.855 (95% CI 0.823‐0.880), outperforming the stand-alone Llama-3.3-70B (0.726, 95% CI 0.704‐0.747), Dynex-QML-8B (0.733, 95% CI 0.709‐0.756), and Llama-3.1-8B (0.602, 95% CI 0.588‐0.615). Compared with Llama 3.3 70B, Dynex-QML (Llama 70B) improved macro-score by 0.128 (95% CI 0.091‐0.163; empirical 2-sided bootstrap
  •  

Circulating tumor DNA-guided de-escalation or escalation of adjuvant therapy in high-risk stage II and stage III colon cancer: the phase 2 PEGASUS trial

Nature Cancer, Published online: 14 September 2026; doi:10.1038/s43018-026-01237-9

Marsoni et al. evaluated the feasibility of a dynamic circulating tumor DNA-guided adjuvant and postadjuvant treatment strategy in patients with resected microsatellite-stable, high-risk stage II or III colon cancer in the phase 2 PEGASUS trial.
  •  

HAT1 regulates glioblastoma cell proliferation and membrane lipid remodeling through ALDH2

Cell Death Discovery, Published online: 14 September 2026; doi:10.1038/s41420-026-03328-z

HAT1 regulates glioblastoma cell proliferation and membrane lipid remodeling through ALDH2
  •  
❌